Breast Cancer Research and Treatment

, Volume 118, Issue 3, pp 599–603 | Cite as

STK15 F31I polymorphism is associated with breast cancer risk: a meta-analysis involving 25,014 subjects

Epidemiology

Abstract

Published data on the association between STK15 F31I polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, Web of Science, and Chinese Biomedicine Database were searched. Crude ORs with 95% CIs were used to assess the strength of association between the STK15 F31I polymorphism and breast cancer risk. The pooled ORs were performed for codominant model (FI vs. FF; II vs. FF), dominant model (FI + II vs. FF), and recessive model (II vs. FI + FF), respectively. A total of 10 studies including 10,537 cases and 14,477 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated with II variant genotype in homozygote comparison and recessive genetic model when all studies were pooled into the meta-analysis (for II vs. FF: OR = 1.23, 95% CI = 1.10–1.37; for recessive model: OR = 1.21, 95% CI = 1.05–1.40). In the subgroup analysis by ethnicity, significantly increased risks were found for II allele carriers among Caucasians (for II vs. FF: OR = 1.24, 95% CI = 1.08–1.43; for recessive model: OR = 1.21, 95% CI = 1.00–1.45); significantly increased risks were also found among Asians for II versus FF (OR = 1.21; 95% CI = 1.01–1.45). In conclusion, this meta-analysis suggests that the STK15 31II allele is a low-penetrant risk factor for developing breast cancer.

Keywords

STK15 Polymorphism Breast cancer Susceptibility Meta-analysis 

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  2. 2.
    Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMedGoogle Scholar
  3. 3.
    Dutertre S, Descamps S, Prigent C (2002) On the role of aurora-A in centrosome function. Oncogene 21:6175–6183CrossRefPubMedGoogle Scholar
  4. 4.
    Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M (2003) Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114:585–598CrossRefPubMedGoogle Scholar
  5. 5.
    Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052–3065CrossRefPubMedGoogle Scholar
  6. 6.
    Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F (2003) Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34:403–412CrossRefPubMedGoogle Scholar
  7. 7.
    Fletcher O, Johnson N, Palles C (2006) Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 98:1014–1018PubMedCrossRefGoogle Scholar
  8. 8.
    Dai Q, Cai QY, Shu XO (2004) Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 13:2065–2070PubMedGoogle Scholar
  9. 9.
    Egan KM, Newcomb PA, Ambrosone CB (2004) STK15 polymorphism and breast cancer risk in a population-based study. Carcinogenesis 25:2149–2153CrossRefPubMedGoogle Scholar
  10. 10.
    Sun T, Miao X, Wang J (2004) Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma. Carcinogenesis 25:2225–2230CrossRefPubMedGoogle Scholar
  11. 11.
    Ewart-Toland A, Dai Q, Gao YT (2005) Aurora-A/STK15 T + 91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 26:1368–1373CrossRefPubMedGoogle Scholar
  12. 12.
    Lo YL, Yu JC, Chen ST (2005) Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK. Int J Cancer 115:276–283CrossRefPubMedGoogle Scholar
  13. 13.
    Cox DG, Hankinson SE, Hunter DJ (2006) Polymorphisms of the AURKA (STK15/Aurora Kinase) gene and breast cancer risk (United States). Cancer Causes Control 17:81–83CrossRefPubMedGoogle Scholar
  14. 14.
    Tchatchou S, Wirtenberger M, Hemminki K (2007) Aurora kinases A and B and familial breast cancer risk. Cancer Lett 247:266–272CrossRefPubMedGoogle Scholar
  15. 15.
    Vidarsdottir L, Bodvarsdottir SK, Hilmarsdottir H, Tryggvadottir L, Eyfjord JE (2007) Breast cancer risk associated with AURKA 91T–> A polymorphism in relation to BRCA mutations. Cancer Lett 250:206–212CrossRefPubMedGoogle Scholar
  16. 16.
    The MARIE-GENICA consortium on genetic susceptibility for menopausal hormone therapy related breast cancer risk (2009) Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat. doi 10.1007/s10549-009-0489-8
  17. 17.
    Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRefGoogle Scholar
  18. 18.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  19. 19.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  20. 20.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629–634PubMedGoogle Scholar
  21. 21.
    Hirschhorn JN, Lohmueller K, Byrne E (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61PubMedCrossRefGoogle Scholar
  22. 22.
    Wacholder S, Chanock S, Garcia-Closas M (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442PubMedGoogle Scholar
  23. 23.
    Munafo MR, Flint J (2004) Meta-analysis of genetic association studies. Trends Genet 20:439–444CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  1. 1.Department of Medical Oncology, Cancer HospitalFudan UniversityShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.Department of Geriatrics, First Affiliated HospitalNanjing Medical UniversityNanjingChina
  4. 4.Department of Epidemiology, School of Public Health and Tropical MedicineSouthern Medical UniversityGuangzhouChina
  5. 5.Department of Respiratory MedicineNanjing Chest HospitalNanjingChina
  6. 6.Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical UniversityAnhuiChina

Personalised recommendations